Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Extended Temozolomide in Recurrent GBM
NCT01115491Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2010
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by Roche. Started Jun 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01115491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01115491.